Lilly shares in development costs and profits for Pfizer’s troubled tanezumab; deal ends
As Pfizer Inc. attempts to get its Phase III pain compound tanezumab out of a partial clinical hold, the company finds a new partner in Eli Lilly & Co., which agreed to share in the development costs and profits of the project.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.